OR WAIT null SECS
Click here to read the articles and download the PDF
Click here to read Pharm Exec's latest listing of the top global biopharma sales producers.
Click here to read the profiles of 13 diverse leaders vital to the future of the biopharma industry.
Click here to read June's Executive Profile on Michelle McMurry-Heath, president and CEO of BIO.
This Pharmaceutical CEO Leadership roundtable brings together pharma Chief Digital Officers and other leaders in the space to discuss the challenges and opportunities associated with digitizing all aspects of the pharma business.
The Healthcare Businesswomen’s Association again names Sandra Horning its WoTY—where the pharma leader’s message of purpose and partnership takes on added resonance today.
With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.
Highlighted Videos
June 09, 2021
Pharm Exec’s latest listing of the top global biopharma sales producers captures the critical business and public health balancing act that was required in the Year of COVID—reinforcing the staying power of building brand value while championing medical innovation.
What are the reasons behind the slump and what does the future hold?
Building on a lifelong passion for biomedical research, and then its application in policy and health equity as a leader in various interconnected settings, Michelle McMurry-Heath, president and CEO of BIO, is uniquely positioned as a “translator” for science and social advocacy—and speaking stakeholders to action.
A business framework for pricing and broader brand strategy.
How the UK is making progress in this hi-tech field.
Leading in a post-quarantine world requires compassion and connection amid employees’ shifting situations.
Pandemic triggers urgency around supply chain initiatives.
Separate pushes for vaccine equity, legislation to lower drug costs.
Looking Back at 1997–1999.
The Biden administration has rolled out a broad initiative to promote domestic production of critical materials, including medicines and their ingredients.
